

# A Rheumatologist's Perspective on OTC Analgesia

Many patients experience a continuum of pain across all stages of osteoarthritis (OA). In conjunction with nonpharmacologic treatments, over-the-counter (OTC) nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen can be effective first-line pharmacologic options because of their availability, relatively low cost, and good safety profile.<sup>1,2</sup>

OTC analgesics have limitations. **WHEN** making an OTC analgesic recommendation for patients with OA, consider:

## WHAT

coexisting medical conditions may be impacted?

### Cardiovascular (CV) disease:



NSAIDs may increase the risk of CV events, including myocardial infarction and stroke.<sup>3-5</sup>

### Gastrointestinal (GI) bleeding:



NSAIDs may promote GI bleeding, and this risk may be greater in patients with a history of stomach ulcers or bleeding problems.<sup>5</sup>

### Kidney disease and other renal insufficiencies:



NSAIDs may increase the risk of acute renal failure.<sup>6-8</sup>

### Liver disease:



Careful consideration should be given when recommending acetaminophen to patients with liver disease.<sup>9</sup>

## WHICH

drug interactions may result from concomitant medication use?

Anticoagulants, steroids, or aspirin taken with NSAIDs

May increase the risk of stomach bleeding<sup>10-12</sup>

Warfarin taken with acetaminophen

May increase the international normalized ratio<sup>9,12</sup>

Multiple acetaminophen-containing products

May increase hepatic risks at supratherapeutic doses<sup>9</sup>

Multiple NSAIDs

May increase the risk of stomach bleeding<sup>5,13</sup>

## WHO

may be at risk for adverse events?

In patients who consume 3 or more alcoholic drinks per day:



NSAIDs may increase the risk of stomach bleeding.<sup>5</sup>



Acetaminophen may increase hepatic risks.<sup>9</sup>

Do your patients understand

## WHY

you recommended a particular analgesic?

When developing a pain management plan for patients with OA, it is essential to explain why a specific analgesic recommendation was made.

Be sure to review how to appropriately use the product, including when to take the medication and how much medication to take at each dose.

Address patients' expectations of how much pain relief is reasonably achievable.

Reinforce the benefits of supportive, nonpharmacologic therapies that can reduce a patient's tendency to reach for additional medications if full pain relief is not achieved.

Education can help patients avoid product misuse and safely achieve relief of their pain.

**“Remember that any treatment option for the management of OA pain has limitations. For patients who do not respond to nonpharmacologic approaches, start with over-the-counter analgesics and escalate only if necessary and appropriate.”**



**Contributor:**  
Andrew J. Sulich, MD

Private Practice Physician,  
Rheumatology and Osteoporosis  
Shores Rheumatology  
St. Clair Shores, Michigan

# A Rheumatologist's Perspective on OTC Analgesia

Many patients experience a continuum of pain across all stages of osteoarthritis (OA). In conjunction with nonpharmacologic treatments, over-the-counter (OTC) nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen can be effective first-line pharmacologic options because of their availability, relatively low cost, and good safety profile.<sup>1,2</sup>

## References

1. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. *Osteoarthritis Cartilage*. 2008;16(2):137-162.
2. Hochberg MC, Altman RD, April KT, et al; American College of Rheumatology. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. *Arthritis Care Res (Hoboken)*. 2012;64(4):465-474.
3. Bavry AA, Khaliq A, Gong Y, et al. Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. *Am J Med*. 2011;124(7):614-620.
4. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA; American Heart Association. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. *Circulation*. 2007;115(12):1634-1642.
5. Motrin IB [product labeling]. Fort Washington, PA: McNeil Consumer Healthcare; 2015.
6. Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. *Expert Opin Drug Saf*. 2009;8(6):669-681.
7. Bush TM, Shlotzhauer TL, Imai K. Nonsteroidal anti-inflammatory drugs: proposed guidelines for monitoring toxicity. *West J Med*. 1991;155(1):39-42.
8. National Kidney Foundation. Pain medicines (analgesics). [https://www.kidney.org/atoz/content/painMeds\\_Analgesics](https://www.kidney.org/atoz/content/painMeds_Analgesics). Accessed August 15, 2016.
9. Tylenol Regular Strength [product labeling]. Fort Washington, PA: McNeil Consumer Healthcare; 2015.
10. Bhatt DL, Scheiman J, Abraham NS, et al; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. *Circulation*. 2008;118(18):1894-1909.
11. García Rodríguez LA, Hernández-Díaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. *Arthritis Res*. 2001;3(2):98-101.
12. US Food and Drug Administration. Organ-specific warnings; internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; final monograph. Final rule. *Fed Regist*. 2009;74(81):19385-19409.
13. Clinard F, Sgro C, Bardou M, et al. Association between concomitant use of several systemic NSAIDs and an excess risk of adverse drug reaction. A case/non-case study from the French Pharmacovigilance system database. *Eur J Clin Pharmacol*. 2004;60(4):279-283.

**“Remember that any treatment option for the management of OA pain has limitations. For patients who do not respond to nonpharmacologic approaches, start with over-the-counter analgesics and escalate only if necessary and appropriate.”**